Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research

被引:704
作者
Giralt, Sergio [1 ]
Ballen, Karen [2 ]
Rizzo, Douglas [3 ]
Bacigalupo, Andreas [4 ]
Horowitz, Mary [3 ]
Pasquini, Marcelo [3 ]
Sandmaier, Brenda [5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[3] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
[4] Hosp San Martino, Genoa, Italy
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
关键词
Reduced intensity conditioning; Definitions; Workshop; NONMYELOABLATIVE PREPARATIVE REGIMENS; PROGENITOR-CELL TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; TERM-FOLLOW-UP; THERAPY; CHEMOTHERAPY; INDUCTION; HSCT;
D O I
10.1016/j.bbmt.2008.12.497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During the 2006 BMT Tandem Meetings, a workshop was convened by the Center for International Blood and Marrow Transplant Research (CIBMTR) to discuss conditioning regimen intensity and define boundaries of reduced-intensity conditioning (RIC) before hematopoietic cell transplantation (HCT). The goal of the workshop was to determine the acceptance of available RIC definitions in the transplant community. Participants were surveyed regarding their opinions on specific statements on conditioning regimen intensity. Questions covered the "Champlin criteria," as well as operational definitions used in registry studies, exemplified in clinical vignettes. A total of 56 participants, including transplantation physicians, transplant center directors, and transplantation nurses, with a median of 12 years of experience in HCT answered the survey. Of these, 67% agreed that a RIC regimen should cause reversible myelosuppression when administered without stem cell support, result in low nonhematologic toxicity, and, after transplantation, result in mixed donor-recipient chimerism at the time of first assessment in most patients. Likewise, the majority (71%) agreed or strongly agreed that regimens including < 500 cGy of total body irradiation as a single fraction or 800 cGy in fractionated doses, busulfan dose < 9 mg/kg, melphalan dose < 140 mg/m(2), or thiotepa dose < 10 mg/kg should be considered RIC regimens. However, only 32% agreed or strongly agreed that the combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) should be considered a RIC regimen. These results demonstrate that although HCT professionals have not reached a consensus on what constitutes a RIC regimen, most accept currently used criteria and operational definitions. These results support the continued use of current criteria for RIC regimens until a consensus statement can be developed.
引用
收藏
页码:367 / 369
页数:3
相关论文
共 15 条
  • [1] AURER I, 1991, BONE MARROW TRANSPL, V7, P255
  • [2] Bacigalupo A, 2004, BONE MARROW TRANSPL, V33, pS29, DOI 10.1038/sj.bmt.1704416
  • [3] Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT)
    Bacigalupo, A
    [J]. BONE MARROW TRANSPLANTATION, 2002, 29 (03) : 191 - 195
  • [4] BACIGALUPO A, 2000, BONE MARROW TRANSPL, V8, P803
  • [5] Champlin R, 1999, ONCOLOGY-NY, V13, P621
  • [6] CHAMPLIN R, 2000, NEW FRONTIERS CANC T, P45
  • [7] CHOPRA R, 1993, BLOOD, V81, P1137
  • [8] Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia
    Clift, RA
    Buckner, CD
    Appelbaum, FR
    Sullivan, KM
    Storb, R
    Thomas, ED
    [J]. BLOOD, 1998, 92 (04) : 1455 - 1456
  • [9] Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
    Giralt, S
    Estey, E
    Albitar, M
    vanBesien, K
    Rondon, G
    Anderlini, P
    OBrien, S
    Khouri, I
    Gajewski, J
    Mehra, R
    Claxton, D
    Andersson, B
    Beran, M
    Przepiorka, D
    Koller, C
    Kornblau, S
    Korbling, M
    Keating, M
    Kantarjian, H
    Champlin, R
    [J]. BLOOD, 1997, 89 (12) : 4531 - 4536
  • [10] Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: Long-term follow-up of the first 285 reported to the National Marrow Donor Program
    Giralt, Sergio
    Logan, Brent
    Rizzo, Douglas
    Zhang, Mei-Je
    Ballen, Karen
    Emmanouilides, Christos
    Nath, Rajneesh
    Parker, Pablo
    Porter, David
    Sandmaier, Brenda
    Waller, Edmund K.
    Barker, Juliet
    Pavletic, Steven
    Weisdorf, Daniel
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (07) : 844 - 852